Abstract Background Atopic dermatitis (AD) is a heterogeneous inflammatory skin disease with different clinical phenotypes based on factors such as age, race, comorbidities, and clinical signs and symptoms. The effect of these factors on therapeutic responses in AD has only been scarcely studied and not for upadacitinib. Currently, there is no biomarker predicting response to upadacitinib.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by D. Thaçi
Risankizumab vs. Fumaric Acid Esters in Plaque Psoriasis
Abstract and Introduction Abstract Background: Fumaric acid esters (FAEs; Fumaderm®) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany. Risankizumab (Skyrizi®) is a humanized IgG1 monoclonal antibody that specifically binds to the p19 subunit of interleukin 23. Objectives: To compare risankizumab treatment to FAEs in patients with psoriasis.
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial - Thaçi - - British Journal of Dermatology - Wiley Online Library
Original Article D. Thaçi, Corresponding Author diamant.thaci@uksh.de orcid.org/0000-0001-8513-550X Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany Correspondence Diamant Thaçi Email: diamant.thaci@uksh.de Contribution: Conceptualization (equal), Data curation (lead), Investigation (lead), Methodology (equal), Supervision (equal), Writing - review & editing (equal) Search for more papers by this author K.
Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study
Summary Background Children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16‐week, randomized, placebo‐controlled, phase III trial in children, dupilumab, a monoclonal antibody inhibiting interleukin (IL)‐4/IL‐13 signalling, significantly improved signs and symptoms with acceptable safety; longer‐term safety and efficacy data are lacking.
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment
Research Letter U. Mrowietz Corresponding Author umrowietz@dermatology.uni-kiel.de orcid.org/0000-0002-9539-0712 Psoriasis‐Center, Department of Dermatology, University Medical Center Schleswig‐Holstein, Campus Kiel, Kiel, Germany Correspondence: Ulrich Mrowietz.
A trial to compare the biologic drug ixekizumab with two other treatments for psoraisis, fumaric acid esters and methotrexate
Summary Plaque psoriasis is a skin disease which causes red, scaly patches of skin. It is a chronic disease, which means that it generally persists for a long time. Medications used to treat plaque psoriasis include a drug called methotrexate and, in some European countries, a medicine called fumaric acid esters (FAE). In more recent years, new, powerful drugs called biologics have been used to treat psoriasis. Ixekizumab is one such biologic treatment for moderate‐to‐severe plaque psoriasis.
比较生物制剂依奇珠单抗与其他两种治疗银屑病的药物富马酸酯和甲氨蝶呤的试验
Summary 斑块型银屑病是一种皮肤病,可引起红色、鳞屑性皮肤斑块。它是一种慢性疾病,这意味着它一般会长期存在。用于治疗斑块型银屑病的药物包括一种称为甲氨蝶呤的药物,在一些欧洲国家,还包括一种称为富马酸酯 (FAE) 的药物。 近年来,被称为生物制剂的新型强效药物被用于治疗银屑病。依奇珠单抗是治疗中重度斑块型银屑病的生物制剂之一。它是一种抗体,意味着机体免疫系统用来抵御疾病的一类蛋白质。 依奇珠单抗可结合并中和白介素‐17A,白介素‐17A 是一种参与皮肤炎症反应并引起银屑病症状的蛋白。以这种方式阻断白介素‐17A 活性是治疗银屑病等疾病的有用方法。 本研究的目的是在一项在慢性中重度斑块型银屑病患者中开展的随机对照试验 (RCT) 中比较依奇珠单抗与甲氨蝶呤和 FAE 的疗效。RCT 试验是指患者被随机分配到正在研究的其中一种药物的治疗组,也有不接受任何正在被比较治疗的对照组。 使用银屑病面积和严重程度指数 (PASI) 评价疗效(治疗成功),PASI 是银屑病病灶(受累皮肤斑片)发红、增厚、鳞屑和程度的指标。PASI 75 表示患者的 PASI 评分自研究开始后至少改善...
The efficacy of secukinumab with continued use in the treatment of psoriasis
Summary Affecting at least 100 million people worldwide, psoriasis is a disease causing red, scaly patches of skin that may cover a large area of the body and may also affect the nails, scalp, palms and soles. This can lead to a severe impairment in quality of life. For patients with moderate to severe disease, the use of drugs called biologic therapies can result in clear or almost clear skin.
A study of dupilumab in the treatment of adolescents with eczema
Summary Atopic dermatitis (AD), also known as eczema, is characterized by red, oozy, and dry skin that can become cracked and infected. Intense itching, which can be very troublesome and can cause sleep disturbance, is the main complaint of patients with AD. AD often begins in childhood and affects 1 in 4 teenagers worldwide.
一项关于 dupilumab 治疗湿疹青少年患者的研究
Summary 特应性皮炎 (AD) 也称为湿疹, 其表现为皮肤发红、渗液和干燥并可能发生开裂和感染。剧烈瘙痒可能非常麻烦, 而且可能导致睡眠障碍, 是 AD 患者的主要主诉。 AD 通常从儿童开始, 而且影响全世界 1/4 的青少年。对于青少年, AD 皮肤的瘙痒和外观可显著降低生活质量,但适合长期使用的中度至重度 AD 有效治疗选择很少。 Dupilumab 是一种新的药物, 其可阻断导致过敏症状(如 AD)的关键分子。研究显示, 该药物对治疗成人中度至重度 AD 是有效的, 而且长期使用相对安全。 这项研究在 40 例年龄 12 至 17 岁的接受 dupilumab 治疗最长一年的患者中进行, 涉及欧洲和加拿大多个中心。研究人员希望了解 dupilumab 是否对治疗 AD 有效以及这类患者长期使用是否安全 。他们还希望了解 dupilumab 在此年龄段 AD 患者中的身体处理方式。 他们发现, dupilumab 治疗在这些年轻患者中显著改善了皮肤和 AD 症状(包括瘙痒), 而且不会造成任何意外的副作用。他们还发现 dupilumab...
苏金单抗持续用于治疗银屑病的疗效
Summary 银屑病影响全球至少 1 亿人, 该疾病导致皮肤出现红色鳞状斑块, 病灶可能会覆盖很大身体面积,也可能影响指甲、头皮、手掌和脚底。这可能导致生活质量严重受损。 对于中度至重度疾病患者, 使用称为生物疗法的药物可能会使皮肤完全康复或几乎完全康复。由于银屑病是一种长期疾病, 因此生物疗法的长期疗效对患者很重要。但有些患者最终可能停止对生物治疗的应答, 这意味着药物不再有效。 患者在多大程度上停止应答, 以及继续治疗时后续恢复应答的比率(意味着治疗再次开始有效)是多少, 尚未在个体患者层面进行这些研究。关于药物治疗疾病(其疗效)的持续能力的研究称为药物稳定性研究。 苏金单抗是银屑病的一种许可的生物疗法,其在大型临床试验中显示具有持久的疗效和安全性。在 16 周的治疗期内,苏金单抗治疗可使银屑病减少 90%,而且研究证明长期疗效长达 5 年。 在本研究中,德国和美国的研究人员研究了苏金单抗在参加两项大型临床试验的人群中的应答稳定性。他们发现,在大多数患者中, 苏金单抗的疗效在一年治疗期内保持稳定, 而且苏金单抗继续治疗可使某些患者恢复失去的疗效。持续应答丧失不常见。...
Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension
Summary Background Dupilumab (monoclonal antibody inhibiting IL‐4/IL‐13 signalling) is approved for use in adolescents aged ≥ 12 years with inadequately controlled moderate‐to‐severe atopic dermatitis (AD). Dupilumab significantly improved AD signs/symptoms in a 16‐week, randomised, placebo‐controlled phase III trial in adolescents (NCT03054428). Objectives To characterize the pharmacokinetics of dupilumab, and long‐term safety and efficacy in adolescents.
A 24‐week multicentre, randomised, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment - Reich - - Briti
Original Article A 24‐week multicentre, randomised, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment K.
A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment
Summary Background Interleukin‐17 antagonists have received a first‐line label for moderate‐to‐severe plaque psoriasis. Objectives We conducted the first head‐to‐head trial between the two most commonly used first‐line therapies in Germany, fumaric acid esters (FAEs) and methotrexate, and the interleukin‐17A antagonist, ixekizumab. Methods Systemic‐naive patients were randomized in this parallel‐group, active‐comparator, open‐label, rater‐blinded trial (each group n = 54).
Sustained Long‐Term Efficacy and Safety of Adalimumab in Pediatric Patients with Severe Chronic Plaque Psoriasis from a Randomised, Double‐Blind, Phase 3 Study - Thaçi - - British Journal of Dermatology - Wiley Online Library
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Original Article Sustained Long‐Term Efficacy and Safety of Adalimumab in Pediatric Patients with Severe Chronic Plaque Psoriasis from a Randomised, Double‐Blind, Phase 3 Study D. Thaçi Corresponding Author E-mail address: Diamant.Thaci@uksh.de Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany Corresponding author Diamant Thaçi, Prof.
Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Original Article Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis A.
Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis
Summary Background The treatment of psoriasis has been revolutionized by the development of biologic therapies. However, the pathogenesis of psoriasis, in particular the role of the cutaneous microbiome, remains incompletely understood. Moreover, skin microbiome studies have relied heavily on 16S rRNA sequencing data in the absence of bacterial culture.
Continued treatment with secukinumab is associated with high retention or regain of response
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Original Article Continued treatment with secukinumab is associated with high retention or regain of response M.
Continued treatment with secukinumab is associated with high retention or regain of response
Clinical Trial M. Augustin Corresponding Author E-mail address: m.augustin@uke.de https://orcid.org/0000-0002-4026-8728 Institute of Health Services Research in Dermatology and Nursing, University Medical Center of Hamburg Eppendorf, Germany Correspondence Matthias Augustin. E‐mail: m.augustin@uke.de Search for more papers by this author † Funding sources Novartis Pharma GmbH, Nuremberg, Germany ‡ Conflicts of interest Conflicts of interest statements are in the Appendix.
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials - Silverberg - 2019 - Br
Clinical Trial Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials J.I. Silverberg Corresponding Author E-mail address: jonathanisilverberg@gmail.com https://orcid.org/0000-0003-3686-7805 Department of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine,...
Long‐term safety of adalimumab in adult patients with plaque psoriasis
Summary Adalimumab is a powerful drug used to treat psoriasis, that has been specially designed to mimic normal human molecules, and for this reason it is classed as a ‘biological’ drug. It reduces inflammation by inhibiting the activity of a chemical ‘cytokine’ in the body called ‘tumour necrosis factor alpha’ (TNF‐alpha). The aim of this study, from the USA, was to assess long‐term safety for patients with psoriasis receiving adalimumab.
British Journal of Dermatology
Summary 阿达木单抗是一种用于治疗银屑病的强力药物,专门被设计模拟正常人体分子,因此被归类为一种“生物”药。它通过抑制身体中一种被称为“肿瘤坏死因子 α” (TNF‐α) 的化学“细胞因子”的活动性来减轻炎症。此项来自美国的研究的目的是评估接受阿达木单抗治疗银屑病患者中的长期安全性。作者们调查了来自 3727 名接受此药患者的数据,作为记录了不良事件(AE,指用药时的不良副作用)的 18 项不同临床试验的一部分。总体而言,5,429.7 名患者‐年龄中有 16,536 例 AE(每 100 患者‐年龄有 304.6 例 AE)。患者‐年龄 (PY) 指患者的数量乘以他们被纳入此研究中的时间长度。最常见的 AE 是鼻咽炎(一种常见的喉部主诉)、上呼吸道感染和头痛(分别为 23.7、12.9 和 7.9 例 AE 每 100 PY)。严重感染、结核和机会性感染的发生率分别为 1.8、0.3 和 0.02 例 AE 每 100 PY。不包括非黑色素瘤性皮肤癌 (NMSC) 的恶性肿瘤(癌症)的发生率为 0.8 例 AE 每 100 PY。NMSC 和黑色素瘤的发生率分别为 0.6...
Comprehensive Long‐Term Safety of Adalimumab from Eighteen Clinical Trials in Adult Patients With Moderate to Severe Plaque Psoriasis
Adalimumab (Humira®; AbbVie Inc., USA) is a fully human monoclonal antibody specific for tumour necrosis factor‐α approved to treat adults with moderate‐to‐severe chronic plaque psoriasis. To assess long‐term safety for patients with psoriasis receiving adalimumab in clinical studies Adalimumab safety data from adults with psoriasis who received ≥1 adalimumab dose in 18 clinical trials were evaluated. Adalimumab was delivered subcutaneously in all treatment regimens.
杜匹鲁单抗结合伴随性局部皮质类固醇治疗对环孢素A应答不充分或不耐受或者在医学上不建议采用环孢素A治疗的过敏性皮肤炎成人患者:安慰剂对照随机阶段III临床试验(LIBERTY AD CAFÉ)
过敏性皮肤炎(又称为AD或湿疹)是一种导致身体大部分皮肤出现瘙痒皮疹的慢性皮肤病,10名成人中就有一名患者。环孢素是常用于AD的口腔治疗药物(口服),药效不稳定,并且有严重的副作用。有时也会使用其他广泛有效的口腔药物,但这些药物未经批准用于AD。杜匹鲁单抗是一种新药物,在很多国家或地区被批准用于控制不足的中度到重度AD成人患者。杜匹鲁单抗专门作用于促进AD的身体通道。欧洲的研究人员评估了杜匹鲁单抗注射对于改善需要环孢素治疗AD,但环孢素无效果、环孢素会导致无法忍受的副作用或者医疗状况不允许使用该药物的患者的皮疹、瘙痒和日常生活的效果。在325名参与者中,110名参与者每周使用一次300...
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical t
Atopic dermatitis (also called AD or eczema) is a chronic skin disease found in up to 1 in 10 adults, causing itchy rashes that may cover most of the body. Ciclosporin, an oral treatment (taken by mouth) commonly used for AD, doesn't always work and can have significant side effects. Other broadly‐acting oral medications are sometimes used, but not approved, for AD. Dupilumab is a new medication approved in many countries for adults with inadequately controlled moderate‐to‐severe AD.
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical t
The present study expands upon previous studies of dupilumab in patients with moderate‐to‐severe atopic dermatitis by evaluating the efficacy and safety of dupilumab with concomitant TCS in patients with atopic dermatitis and a history of inadequate response or intolerance to CsA, or CsA‐naïve patients for whom CsA treatment was medically inadvisable.
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical t
Table S3 Baseline characteristics: subgroups based on prior ciclosporin A use (a); subgroups based on baseline disease severity (Investigator's Global Assessment score 3 or 4) (b). Table S4 Mean change from baseline at Week 16 in Eczema Area and Severity Index, SCORing Atopic Dermatitis, weekly average of peak pruritus numerical rating scale, Dermatology Life Quality Index and Patient‐Oriented Eczema Measure; multiple imputation method with censoring after rescue treatment.
Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase
Atopic dermatitis (AD) is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely-used, potent immunosuppressant for AD. CsA is not effective in all patients, and side effects limit its use.
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical t
The present study expands upon previous studies of dupilumab in patients with moderate‐to‐severe atopic dermatitis by evaluating the efficacy and safety of dupilumab with concomitant TCS in patients with atopic dermatitis and a history of inadequate response or intolerance to CsA, or CsA‐naïve patients for whom CsA treatment was medically inadvisable.
Secukinumab is Superior to Fumaric Acid Esters in Treating Subjects with Moderate to Severe Plaque Psoriasis who are Naïve to Systemic Treatments: Results from the Randomized Controlled PRIME Trial - Sticherling - 2017 - British Journal of Dermatology - W
Secukinumab is a fully human antibody that neutralizes IL-17A and has significant efficacy and a favorable safety profile in moderate to severe plaque psoriasis and psoriatic arthritis. In this 24-week, randomized, open-label, multicenter study with blinded assessment, subjects with moderate to severe plaque psoriasis, naïve to systemic treatments, were randomized to receive secukinumab 300 mg subcutaneously or oral fumaric acid esters (FAE).
Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study - Bissonnette - 2017 - British Journal of Dermatology - Wiley Online Library
Secukinumab has demonstrated significant efficacy with a good safety profile through 1 year in plaque psoriasis. Given the chronic nature of this disease, long-term follow-up is needed to fully evaluate psoriasis therapies. Subjects completing 52 weeks of secukinumab treatment in the SCULPTURE core study entered an extension in which they continued the same double-blind regimens.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with D.
Contact D., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack